Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111369 | PMC |
| http://dx.doi.org/10.1111/apa.16345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics, risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia: a retrospective real-world study of inpatients.
BMC Pharmacol Toxicol
January 2025
Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, 28 Fu Xing Road, Beijing, 100853, China.
Objective: The occurrence of hypofibrinogenemia after tocilizumab treatment has attracted increasing attention, which may cause bleeding and even life-threatening. This study aims to explore the risk factors for tocilizumab-induced hypofibrinogenemia (T-HFIB) and construct a risk prediction model.
Methods: A total of 221 inpatients that received tocilizumab from 2015 to 2023 were retrospectively collected and divided into T-HFIB group or control group.
Comparative Analysis of Systemic Immune Responses and Metastatic Risks in Tumor Ablation: An Animal Study of Radiofrequency Ablation and Irreversible Electroporation with Immune Modulation.
Cardiovasc Intervent Radiol
January 2025
Department of Immunology, Faculty of Medicine, Kindai University, Osaka, Japan.
Purpose: This study aimed to compare systemic immune responses and metastatic effects induced by radiofrequency ablation (RFA) and irreversible electroporation (IRE) in murine tumor models. We assessed cytokine production, growth of treated and untreated metastatic tumors, and synergy with immune checkpoint inhibitors (ICIs).
Materials And Methods: Hep55.
A simple LC-MS/MS assay for the quantification of E6011, a novel anti-fractalkine monoclonal antibody, in cynomolgus monkey serum - comparison with ligand binding assay.
J Pharm Biomed Anal
December 2024
Global Drug Metabolism and Pharmacokinetics, Eisai Co., Ltd., Tokodai 5-1-3, Tsukuba-shi, Ibaraki 300-2635, Japan; Laboratory of Genomics-based Drug Discovery, Faculty of Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. Electronic address:
E6011 is a monoclonal antibody that is currently under development for the treatment of rheumatoid arthritis. While ligand binding assays (LBAs) are typically employed for the determination of therapeutic antibodies, ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) represents an alternative platform. E6011 in monkey serum was treated with ammonium sulfate to obtain pellets for subsequent processing.
View Article and Find Full Text PDFNoninvasive identification of HER2 status by integrating multiparametric MRI-based radiomics model with the vesical imaging-reporting and data system (VI-RADS) score in bladder urothelial carcinoma.
Abdom Radiol (NY)
January 2025
First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Purpose: HER2 expression is crucial for the application of HER2-targeted antibody-drug conjugates. This study aims to construct a predictive model by integrating multiparametric magnetic resonance imaging (mpMRI) based multimodal radiomics and the Vesical Imaging-Reporting and Data System (VI-RADS) score for noninvasive identification of HER2 status in bladder urothelial carcinoma (BUC).
Methods: A total of 197 patients were retrospectively enrolled and randomly divided into a training cohort (n = 145) and a testing cohort (n = 52).
Background: Recent advances in diagnostics have made it possible to identify early signs of the pathophysiological changes underlying Alzheimer's Disease (AD) via blood tests. However, the use of blood-based biomarkers (BBBMs) for the early detection of AD may be limited in primary care settings despite its potential for wide access and early detection of AD (PMID: 37295421) Therefore, there is a need to understand the barriers and facilitators of BBBM testing for AD in primary care.
Method: We employed a combination of qualitative research, advisory board, and quantitative survey to engage with clinical/scientific advisors and community-based physicians in primary care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!